NovoCure Limited growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +8.5%
EBITDA: -58.7%
EBIT: -9.9%
EPS: -1.3%
Free cash flow: +33.4%
Operating cash flow: +11.7%

Forward estimates

Revenue: +7.2%
EBITDA: +13.7%
EPS: +16.3%

Three-year CAGR

Revenue: +6.8%
EBITDA: -8.6%
EBIT: +9.8%
Net income: +19.2%
EPS: +21.8%
Free cash flow: -9.3%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.